Last updated on July 2019

A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas


Brief description of study

The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements.

This is a randomized, open-label, parallel-group, multi-center trial in adult subjects with Relapsed or refractory (R/R) aggressive Non-Hodgkin lymphoma (NHL) to compare safety and efficacy between the standard of care (SOC) strategy versus JCAR017 (also known as lisocabtagene maraleucel or liso-cel). Subjects will be randomized to either receive SOC (Arm

  1. or to receive JCAR017 (Arm B).

All subjects randomized to Arm A will receive Standard of care (SOC) salvage therapy (R-DHAP, RICE or R-GDP) as per physician's choice before proceeding to High dose chemotherapy (HDCT) and Hematopoietic stem cell transplant (HSCT).

Subjects from Arm A may be allowed to cross over and receive JCAR017 upon confirmation of an EFS event.

Subjects randomized to Arm B will receive Lymphodepleting (LD) chemotherapy followed by JCAR017 infusion.

Clinical Study Identifier: NCT03575351

Find a site near you

Start Over

Virginia G Piper Cancer Center

Scottsdale, AZ United States
  Connect »

Mayo Clinic Arizona

Scottsdale, AZ United States
  Connect »

Mayo Clinic - Jacksonville

Jacksonville, FL United States
  Connect »

Emory University

Atlanta, GA United States
  Connect »

University of Michigan

Ann Arbor, MI United States
  Connect »

University of Minnesota

Minneapolis, MN United States
  Connect »

Mayo Clinic - Rochester

Rochester, MN United States
  Connect »

Levine Cancer Institute

Charlotte, NC United States
  Connect »

UZ Gent

Gent, Belgium
  Connect »

Institut Gustave Roussy

Villejuif CEDEX, France
  Connect »

UCL Cancer Institute

London, United Kingdom
  Connect »

Gustave Roussy

Villejuif CEDEX, France
  Connect »